Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. (Nasdaq: HYPR) is a health technology and medical device company that focuses its news flow on developments around the Swoop® Portable MR Imaging® System, an FDA-cleared, portable, ultra-low-field brain MRI platform. Company press releases emphasize regulatory milestones, clinical studies, financial results, and global health initiatives tied to this AI-powered portable MRI technology.
Investors and clinicians following HYPR news can expect regular updates on clinical research and indication expansion efforts. Recent announcements include the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center trial designed to evaluate contrast-enhanced ultra-low-field portable MRI to support a future FDA submission for expanded intended use of the Swoop® system with gadolinium-based contrast agents. Other clinical news has highlighted the PRISM PMR study, which evaluates the Swoop® system’s use in neurosurgical operating room settings, and a peer-reviewed publication describing the economic impact of integrating the Swoop® system into acute hospital care.
Hyperfine’s news feed also features regulatory and market access updates, such as regulatory approval of the Swoop® system in India by the Central Drugs Standard Control Organization (CDSCO), as well as CE Mark and UKCA Mark approvals for its Optive AI™ software. Financial and corporate news includes quarterly and preliminary unaudited financial results, capital raises through public offerings, participation in healthcare conferences, and business updates related to the commercial rollout of the next generation Swoop® system and Optive AI™ software.
For those tracking HYPR, the news stream provides insight into the company’s progress in hospital and neurology office adoption, its international expansion, and its collaborations on global brain health projects such as the UNITY initiative. Bookmarking this page allows readers to monitor how Hyperfine’s clinical, regulatory, and financial developments evolve over time.
Hyperfine (Nasdaq: HYPR) participated in the 2024 ASNR Annual Meeting held in Las Vegas from May 18-22, 2024. The event highlighted the use of the Swoop® Portable MR Imaging® system, particularly for Alzheimer's care. Presenters emphasized the critical role of MRI in diagnosing and managing Alzheimer's disease and the potential of portable MR imaging to fill existing gaps in diagnostic capabilities. Sessions focused on the importance of monitoring amyloid-related imaging abnormalities (ARIA) for safe Alzheimer’s treatments. Attendees expressed significant enthusiasm for the Swoop® system’s benefits in clinical settings.
Hyperfine (Nasdaq: HYPR) announced its Q1 2024 financial results on May 13, 2024. The company reported $3.30 million in revenue, a 25% increase from Q1 2023, and sold 13 Swoop® systems. Gross margin improved to $1.35 million. R&D expenses were $5.57 million, and SG&A expenses dropped to $6.43 million. Net loss decreased to $9.85 million ($0.14 per share) from $12.16 million ($0.17 per share) in Q1 2023. Key milestones include starting the CARE PMR Alzheimer’s study, enrolling over 100 patients in the ACTION PMR stroke study, and launching the 8th-gen AI-powered software. Full-year 2024 revenue is expected to be $12-$15 million with a $40 million cash burn.
Hyperfine, Inc. (Nasdaq: HYPR) has appointed distributors in France, the UK, and Italy to expand the market reach of its portable MR brain imaging system, Swoop®. The company has obtained CE certification and UKCA certification for its latest hardware and AI-powered software. The move aims to meet the global demand for accessible MR brain imaging, with a focus on Alzheimer's disease and acute stroke applications. Enrico Barini joins as International Business Development Director to lead the European market expansion.
Hyperfine, Inc. (Nasdaq: HYPR) will announce its first quarter 2024 financial results on May 13, 2024. The company, known for its FDA-cleared portable MR brain imaging system, the Swoop® system, will host a conference call on the same day. The event can be accessed via the Investors page of Hyperfine, Inc.'s website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.